IL274248B2 - Compounds and preparations for the treatment of hematological disorders - Google Patents
Compounds and preparations for the treatment of hematological disordersInfo
- Publication number
- IL274248B2 IL274248B2 IL274248A IL27424820A IL274248B2 IL 274248 B2 IL274248 B2 IL 274248B2 IL 274248 A IL274248 A IL 274248A IL 27424820 A IL27424820 A IL 27424820A IL 274248 B2 IL274248 B2 IL 274248B2
- Authority
- IL
- Israel
- Prior art keywords
- compound
- leukemia
- lymphoma
- nhl
- dlbcl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579502P | 2017-10-31 | 2017-10-31 | |
| PCT/US2018/058194 WO2019089580A1 (en) | 2017-10-31 | 2018-10-30 | Compounds and compositions for treating hematological disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL274248A IL274248A (en) | 2020-06-30 |
| IL274248B1 IL274248B1 (en) | 2024-02-01 |
| IL274248B2 true IL274248B2 (en) | 2024-06-01 |
Family
ID=66328095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL274248A IL274248B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL315025A IL315025A (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL308364A IL308364B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315025A IL315025A (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
| IL308364A IL308364B2 (en) | 2017-10-31 | 2018-10-30 | Compounds and preparations for the treatment of hematological disorders |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10758518B2 (enExample) |
| EP (2) | EP4410377A3 (enExample) |
| JP (3) | JP7241747B2 (enExample) |
| KR (2) | KR20240130818A (enExample) |
| CN (2) | CN111225911B (enExample) |
| AU (3) | AU2018359248B2 (enExample) |
| BR (1) | BR112020008214A2 (enExample) |
| CA (1) | CA3079628A1 (enExample) |
| DK (1) | DK3704108T3 (enExample) |
| EA (1) | EA202090497A1 (enExample) |
| ES (1) | ES2979273T3 (enExample) |
| FI (1) | FI3704108T3 (enExample) |
| HR (1) | HRP20240700T1 (enExample) |
| HU (1) | HUE067356T2 (enExample) |
| IL (3) | IL274248B2 (enExample) |
| LT (1) | LT3704108T (enExample) |
| MX (2) | MX2020003666A (enExample) |
| MY (1) | MY203827A (enExample) |
| NZ (1) | NZ762393A (enExample) |
| PH (1) | PH12020550457A1 (enExample) |
| PL (1) | PL3704108T3 (enExample) |
| PT (1) | PT3704108T (enExample) |
| RS (1) | RS65572B1 (enExample) |
| SG (1) | SG11202002386WA (enExample) |
| SI (1) | SI3704108T1 (enExample) |
| SM (1) | SMT202400216T1 (enExample) |
| WO (1) | WO2019089580A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311677B2 (en) | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| WO2018178947A2 (en) | 2017-03-31 | 2018-10-04 | Aurigene Discovery Technologies Limited | Compounds and compositions for treating hematological disorders |
| MY203827A (en) * | 2017-10-31 | 2024-07-19 | Curis Inc | Compounds and compositions for treating hematological disorders |
| MX2022003504A (es) * | 2019-09-24 | 2022-07-19 | Shanghai Meiyue Biotech Dev Co Ltd | Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo. |
| BR112022019987A2 (pt) | 2020-04-07 | 2022-11-22 | Bayer Ag | Tiazolpiridinas substituídas, seus sais e uso dos mesmos como substâncias herbicidamente ativas |
| IL300310A (en) * | 2020-08-03 | 2023-04-01 | Curis Inc | Preparations and methods for treating diseases and disorders |
| JP2023550739A (ja) * | 2020-11-18 | 2023-12-05 | キュリス，インコーポレイテッド | 疾患及び障害を治療する方法 |
| EP4269409A4 (en) * | 2020-12-25 | 2024-12-11 | Medshine Discovery Inc. | AMIDE-OXAZOLE COMPOUND |
| AU2022254933A1 (en) * | 2021-04-08 | 2023-11-09 | Curis, Inc. | Combination therapies for the treatment of cancer |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| CN117177965B (zh) | 2021-12-23 | 2024-04-30 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
| WO2025090844A1 (en) * | 2023-10-27 | 2025-05-01 | Curis, Inc. | Methods of treating cancer associated with reduced interleukin 1 beta expression |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014190163A2 (en) * | 2013-05-22 | 2014-11-27 | Children's Hospital Medical Center | Combination therapy for mds |
| WO2015104688A1 (en) * | 2014-01-13 | 2015-07-16 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| WO2017023941A1 (en) * | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| RU2142937C1 (ru) | 1990-05-18 | 1999-12-20 | Хехст АГ | Амиды органических кислот, способ их получения и фармацевтическая композиция |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| US6403609B1 (en) | 1997-07-29 | 2002-06-11 | Alcon Manufacturing, Ltd. | Ophthalmic compositions containing galactomannan polymers and borate |
| CA2318920A1 (en) | 1998-01-29 | 1999-08-05 | James W. Young | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| DE602004029242D1 (en) | 2003-05-01 | 2010-11-04 | Bristol Myers Squibb Co | Pyrazolamidverbindungen |
| CA2526361C (en) | 2003-05-20 | 2012-05-15 | Ajinomoto Co., Inc. | Amide derivative |
| EP1628661A2 (en) | 2003-06-05 | 2006-03-01 | Vertex Pharmaceuticals Incorporated | Modulators of vr1 receptor |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| US20050197364A1 (en) | 2003-10-07 | 2005-09-08 | Kelly Michael G. | Amide compounds as ion channel ligands and uses thereof |
| CA2563941C (en) | 2004-04-22 | 2014-10-07 | Bayer Cropscience Lp | Method and composition for controlling weeds with a combination of a preemergent, a post emergent and a three-way broadleaf herbicidal compositions |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| CA2589695A1 (en) | 2004-12-17 | 2006-06-22 | Eli Lilly And Company | Thiazolopyridinone derivates as mch receptor antagonists |
| DE602005009021D1 (de) | 2004-12-17 | 2008-09-25 | Lilly Co Eli | Neue mch-rezeptorantagonisten |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| JP5188988B2 (ja) | 2006-02-10 | 2013-04-24 | トランステック ファーマ，インコーポレイティド | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| WO2007121154A2 (en) | 2006-04-11 | 2007-10-25 | Janssen Pharmaceutica, N.V. | Substituted benzothiazole kinase inhibitors |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| CN101616910A (zh) | 2006-09-07 | 2009-12-30 | 比奥根艾迪克Ma公司 | 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| CA2690619A1 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
| NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| CA2743609A1 (en) | 2008-11-19 | 2010-05-27 | Schering Corporation | Inhibitors of diacylglycerol acyltransferase |
| US8283360B2 (en) | 2008-12-19 | 2012-10-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic derivatives and methods of use thereof |
| JP2012513435A (ja) | 2008-12-23 | 2012-06-14 | エフ．ホフマン−ラ ロシュ アーゲー | Ｐ２ｘ７調節薬としてのジヒドロピリドンアミド |
| WO2011046954A1 (en) | 2009-10-13 | 2011-04-21 | Ligand Pharmaceuticals Inc. | Hematopoietic growth factor mimetic small molecule compounds and their uses |
| CN102939283B (zh) | 2010-04-22 | 2015-06-03 | 詹森药业有限公司 | 可用作己酮糖激酶抑制剂的吲唑化合物 |
| CA2793697A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Inhibitors of phosphoinositide dependent kinase 1 (pdk1) |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| MX340490B (es) | 2010-07-13 | 2016-07-11 | F Hoffmann-La Roche Ag * | Derivados de pirazolo [1, 5a] pirimidina y de tieno [3, 2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4). |
| KR20180099933A (ko) | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | 복소환 아민 및 이의 용도 |
| MX2013007149A (es) | 2010-12-20 | 2013-10-30 | Merck Serono Sa | Derivados de indazoliltriazol como inhibidores de cinasas asociadas con el receptor de interleucinas-1 (irak). |
| WO2012142125A2 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| BR112014009531A8 (pt) | 2011-10-20 | 2018-01-16 | Glaxosmithkline Llc | aza-heterociclos bicíclicos substituídos e análogos como moduladores de sirtuína |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| HK1210696A1 (en) | 2012-07-11 | 2016-05-06 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| WO2014070979A1 (en) | 2012-11-03 | 2014-05-08 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| SG11201605408RA (en) * | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| KR20160118345A (ko) | 2014-02-06 | 2016-10-11 | 애브비 인코포레이티드 | 6-헤테로아릴옥시- 및 6-아릴옥시-퀴놀린-2-카복사미드 및 이의 용도 |
| US20170152263A1 (en) * | 2014-06-20 | 2017-06-01 | Aurigene Discovery Technologies Limited | Substituted Indazole Compounds as IRAK4 Inhibitors |
| US20180201609A1 (en) | 2015-07-15 | 2018-07-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| US20210292843A1 (en) | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| MY203827A (en) * | 2017-10-31 | 2024-07-19 | Curis Inc | Compounds and compositions for treating hematological disorders |
-
2018
- 2018-10-30 MY MYPI2020001530A patent/MY203827A/en unknown
- 2018-10-30 IL IL274248A patent/IL274248B2/en unknown
- 2018-10-30 RS RS20240586A patent/RS65572B1/sr unknown
- 2018-10-30 WO PCT/US2018/058194 patent/WO2019089580A1/en not_active Ceased
- 2018-10-30 NZ NZ762393A patent/NZ762393A/en unknown
- 2018-10-30 IL IL315025A patent/IL315025A/en unknown
- 2018-10-30 HR HRP20240700TT patent/HRP20240700T1/hr unknown
- 2018-10-30 PT PT188737787T patent/PT3704108T/pt unknown
- 2018-10-30 DK DK18873778.7T patent/DK3704108T3/da active
- 2018-10-30 FI FIEP18873778.7T patent/FI3704108T3/fi active
- 2018-10-30 CN CN201880066904.0A patent/CN111225911B/zh active Active
- 2018-10-30 KR KR1020247027492A patent/KR20240130818A/ko active Pending
- 2018-10-30 JP JP2020523028A patent/JP7241747B2/ja active Active
- 2018-10-30 SI SI201831106T patent/SI3704108T1/sl unknown
- 2018-10-30 HU HUE18873778A patent/HUE067356T2/hu unknown
- 2018-10-30 EP EP24168755.7A patent/EP4410377A3/en active Pending
- 2018-10-30 KR KR1020207013352A patent/KR102697663B1/ko active Active
- 2018-10-30 CA CA3079628A patent/CA3079628A1/en active Pending
- 2018-10-30 ES ES18873778T patent/ES2979273T3/es active Active
- 2018-10-30 BR BR112020008214-7A patent/BR112020008214A2/pt not_active Application Discontinuation
- 2018-10-30 EP EP18873778.7A patent/EP3704108B1/en active Active
- 2018-10-30 SM SM20240216T patent/SMT202400216T1/it unknown
- 2018-10-30 CN CN202311020285.0A patent/CN117064897A/zh active Pending
- 2018-10-30 LT LTEPPCT/US2018/058194T patent/LT3704108T/lt unknown
- 2018-10-30 AU AU2018359248A patent/AU2018359248B2/en active Active
- 2018-10-30 EA EA202090497A patent/EA202090497A1/ru unknown
- 2018-10-30 MX MX2020003666A patent/MX2020003666A/es unknown
- 2018-10-30 IL IL308364A patent/IL308364B2/en unknown
- 2018-10-30 PL PL18873778.7T patent/PL3704108T3/pl unknown
- 2018-10-30 SG SG11202002386WA patent/SG11202002386WA/en unknown
- 2018-10-31 US US16/176,940 patent/US10758518B2/en active Active
-
2020
- 2020-04-21 PH PH12020550457A patent/PH12020550457A1/en unknown
- 2020-07-13 MX MX2023010882A patent/MX2023010882A/es unknown
- 2020-07-21 US US16/934,724 patent/US20200345704A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/566,371 patent/US20220370422A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034551A patent/JP7476380B2/ja active Active
- 2023-08-30 AU AU2023222890A patent/AU2023222890B2/en active Active
-
2024
- 2024-04-17 JP JP2024066487A patent/JP2024096919A/ja not_active Withdrawn
-
2025
- 2025-07-10 AU AU2025205341A patent/AU2025205341A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014190163A2 (en) * | 2013-05-22 | 2014-11-27 | Children's Hospital Medical Center | Combination therapy for mds |
| WO2015104688A1 (en) * | 2014-01-13 | 2015-07-16 | Aurigene Discovery Technologies Limited | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| WO2017023941A1 (en) * | 2015-08-04 | 2017-02-09 | Rigel Pharmaceuticals, Inc. | Benzazole compounds and methods for making and using the compounds |
Non-Patent Citations (1)
| Title |
|---|
| BOOHER ROBERT ET AL:, COMBINATION OF IRAK4 INHIBITOR CA-4948 WITHBCL2 INHIBITOR VENETOCLAX INDUCES TUMOR REGRESSION IN AN ABC-DLBCLXENOGRAFT MODEL, 8 December 2017 (2017-12-08) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL274248B2 (en) | Compounds and preparations for the treatment of hematological disorders | |
| MX2019001043A (es) | Metodos y composiciones para el tratamiento de la mielofibrosis. | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| MX2023005160A (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma. | |
| EA201992322A3 (ru) | Соединения и композиции для лечения гематологических расстройств | |
| PH12022551546A1 (en) | Carboxy derivatives with antiinflamatory properties. | |
| MX2021003478A (es) | Compuestos utiles como inhibidores de cinasa. | |
| GEAP202415986A (en) | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | |
| PH12022550286A1 (en) | Deuterated compounds for use in the treatment of cancer | |
| MX2018004832A (es) | Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer. | |
| NZ596583A (en) | Substituted dihydropyrazolones for treating cardiovascular and haematological diseases | |
| NZ708249A (en) | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor | |
| MX2019015204A (es) | Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. | |
| MY198004A (en) | Antitumoral compounds | |
| MX2019006079A (es) | Derivados de oxoisoquinolina novedosos. | |
| IN2012DN01983A (enExample) | ||
| MX2022005767A (es) | Combinacion de un inhibidor de tirosina cinasa de bruton (btk) y un inhibidor de homologo de doble minuto murino (mdm2) para tratamiento de cancer. | |
| MX2019002019A (es) | Compuestos de beta-amino-isoquinolinil amida. | |
| MX2020001979A (es) | Macrociclo que contiene aminopirazol y pirimidina y composicion farmaceutica y uso de la misma. | |
| WO2016018511A3 (en) | Methods and compositions for treatment of her-positive cancers | |
| MX2018011046A (es) | Composiciones y metodos para tratar canceres. | |
| WO2017040801A3 (en) | Methods for making and using an immunoconjugate for the treatment of cancer | |
| SA515370253B1 (ar) | مركب أميد عطري غير متجانس الحلقة يحتوي على نتروجين ثنائي الحلقة | |
| WO2016159575A3 (ko) | 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법 | |
| WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES |